 | | Vol. 15.11 – 9 April, 2024 |
| |
|
|
| Scientists revealed forkhead box O1 (FOXO1) as a key transcription factor for autonomous cold adaptation. Promoting FOXO1 nuclear entry enhanced cold tolerance in pre-diabetic obese mice, and greatly prolonged the shelf-life of human and mouse pancreatic tissues and islets.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| | The authors evaluated lipidome alterations caused by type 1 and type 2 diabetes by determining lipids significantly associated with diabetes overall and in both sexes, and lipids associated with the glycemic state.
[Cardiovascular Diabetology] |
|
|
|
| Researchers performed ex vivo glucose-stimulated insulin secretion and insulin content assays in islets of 213 mice from 13 inbred mouse strains on chow, western diet, and ketogenic diet.
[American Journal Of Physiology-Endocrinology And Metabolism] |
| |
|
|
| Investigators showed that ubiquitin conjugating enzyme E2F (UBE2F) was essential for the growth of human pancreatic cancer cells with KRAS mutations.
[Developmental Cell] |
|
|
|
| Scientists investigated the role of MUC1, a mucin protein overexpressed in pancreatic cancer, in regulating polyamine metabolism.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| By screening anticancer metabolic compounds, the authors identified an inhibitor of lysine-specific histone demethylase 1A, which dramatically decreased the growth of PDAC and showed an anti-tumoral effect in tumor-bearing mice.
[Cell Death Discovery] |
|
|
|
| Investigators explored the role of interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) in the development and progression of pancreatic cancer. Their data indicated that IFIT1 increased pancreatic cancer cell proliferation, migration, and invasion by activating the Wnt/β-catenin pathway.
[Cellular Oncology] |
|
|
|
|
| The authors highlight the complex nature of diabetes mellitus, and explore the multifaceted role of the Fabkin complex in glucose metabolism, insulin resistance, anti-inflammation, beta cell proliferation, and vascular function.
[Biochemical Pharmacology] |
|
|
|
|
| The Pancreatic Cancer Action Network announced Dr. Anna Berkenblit, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.
[Pancreatic Cancer Action Network] |
|
|
|
|
| May 20, 2024
New York, New York, United States & Online |
|
|
|
|
|
| | Pancreatic Cancer Canada – Toronto, Ontario, Canada |
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | The University of Chicago – Chicago, Illinois, United States |
|
|
|
| | University of Colorado – Aurora, Colorado, United States |
|
|
|
| | Boston University – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
